AUPH
HealthcareAurinia Pharmaceuticals Inc. · Biotechnology · $2B
What is Aurinia Pharmaceuticals Inc.?
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company focused on treating diseases with significant unmet medical need. Its lead product, LUPKYNIS, is approved for adult patients with active lupus nephritis in the United States and internationally.
Aurinia generates revenue primarily through the commercialization of LUPKYNIS, a targeted therapy for lupus nephritis — a serious kidney condition caused by systemic lupus erythematosus. The company operates in the United States and pursues international markets through a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. This partnership extends LUPKYNIS's global reach while allowing Aurinia to focus its resources on domestic commercialization and pipeline development.
Aurinia was founded in 2014 and is headquartered in Victoria, Canada.
- LUPKYNIS — approved therapy for active lupus nephritis in adults
- Otsuka collaboration for international commercialization rights
- Pipeline programs targeting autoimmune and inflammatory diseases
Is AUPH a Good Stock to Buy?
UQS Score rates AUPH as Very Good overall.
Aurinia's strongest attributes lie in its Quality and Risk pillars, both rated Strong — reflecting a business that has navigated the transition from development to commercial stage with financial discipline. The Growth pillar earns a Good rating, consistent with a company building revenue momentum behind a recently launched specialty drug.
The Moat pillar sits at Neutral, which is typical for single-product biopharma companies where competitive positioning depends heavily on patent protection and clinical differentiation rather than broad structural advantages.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AUPH pay dividends?
No — Aurinia Pharmaceuticals Inc. does not currently pay a dividend.
Aurinia does not currently pay a dividend. As a commercial-stage biopharma company, capital is directed toward expanding LUPKYNIS's market penetration, supporting its Otsuka partnership, and funding ongoing research. This reinvestment approach is standard for specialty pharmaceutical companies at Aurinia's stage of growth.
When does AUPH report earnings?
Aurinia Pharmaceuticals reports earnings on a quarterly cadence, typical for US-listed equities.
Aurinia's recent reporting periods have reflected the ongoing commercial ramp of LUPKYNIS, with revenue trends tied closely to prescription growth and payer access dynamics. Investors watch gross-to-net adjustments and operating expense discipline as key indicators of the company's path toward profitability.
For the most recent quarter's results, visit Aurinia Pharmaceuticals' investor relations page directly.
AUPH Price History
+9.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Aurinia Pharmaceuticals Inc.?
Based on Aurinia Pharmaceuticals Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AUPH Long-term Outlook
Aurinia's fundamental outlook is shaped by the continued commercial adoption of LUPKYNIS in a patient population that has historically been underserved. The Good Growth rating suggests the company is building revenue traction, while the Strong Risk rating indicates the balance sheet and operational profile are relatively well-managed for a single-product biopharma. The Valuation pillar is rated Good, suggesting the market's current pricing reflects a reasonable view of near-term prospects without extreme premium.
Growth drivers
- Expanding LUPKYNIS prescription volume in the US lupus nephritis market
- International revenue contributions through the Otsuka licensing partnership
- Potential label expansions or pipeline candidates targeting autoimmune conditions
Key risks
- Single-product revenue concentration creates vulnerability to competitive or regulatory disruption
- Payer coverage and reimbursement dynamics can limit commercial uptake
- Valuation sensitivity to clinical or commercial setbacks common in specialty biopharma
AUPH vs Peers
Aurinia operates in a competitive specialty biopharma landscape alongside other mid- and small-cap companies focused on niche therapeutic areas.
Syndax focuses on oncology with a pipeline centered on epigenetic mechanisms, contrasting with Aurinia's autoimmune and nephrology focus.
Ocular Therapeutix targets ophthalmic conditions using sustained-release drug delivery technology, a distinct therapeutic area from Aurinia's lupus nephritis franchise.
Mesoblast pursues cell-based therapies for inflammatory and cardiovascular diseases, representing a different modality than Aurinia's small-molecule approach.
Frequently Asked Questions
What does Aurinia Pharmaceuticals do?
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for diseases with unmet medical need. Its primary product, LUPKYNIS, is approved for the treatment of adult patients with active lupus nephritis. The company also has a licensing agreement with Otsuka Pharmaceutical for international distribution.
Does AUPH pay dividends?
Aurinia does not pay a dividend. The company reinvests available capital into commercializing LUPKYNIS and supporting its international partnership with Otsuka. This is consistent with the approach of most commercial-stage specialty biopharma companies that are still scaling revenue.
When does AUPH report earnings?
Aurinia Pharmaceuticals reports on a quarterly cadence, as is standard for US-listed companies. For confirmed dates and the most recent financial results, check the investor relations section of Aurinia's official website.
Is AUPH a good stock to buy?
UQS Score rates AUPH as Very Good, with Strong ratings in both Quality and Risk, and Good ratings in Growth and Valuation. Whether it suits your portfolio depends on your risk tolerance and investment goals. The full pillar breakdown is available to UQS Pro members.
Is AUPH overvalued?
The UQS Valuation pillar for AUPH is rated Good, suggesting the stock is not trading at an extreme premium relative to its fundamentals. Valuation in biopharma is often sensitive to commercial milestones, so ongoing monitoring is worthwhile. Pro members can view the detailed valuation metrics behind this rating.
How does AUPH compare to its competitors?
Aurinia is differentiated by its focus on autoimmune kidney disease and its single approved commercial product, LUPKYNIS. Peers like Syndax, Ocular Therapeutix, and Mesoblast operate in distinct therapeutic areas with different modalities, making direct comparisons more about stage and risk profile than head-to-head competition.
What is AUPH's market cap bracket?
Aurinia Pharmaceuticals is classified as a mid-cap company. This places it in a range that typically offers more liquidity than small-cap biopharma names while still carrying meaningful growth potential tied to its commercial product's adoption trajectory.
Who founded Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals was established in 2014. Founding and leadership history is publicly available through the company's official website and regulatory filings for those seeking detailed background on the executive team.
Is AUPH a long-term quality stock?
From a quality indicator perspective, AUPH's Strong Quality and Strong Risk pillar ratings suggest a company with a relatively disciplined financial profile for its stage. Long-term sustainability will depend on LUPKYNIS's market penetration and whether Aurinia can broaden its pipeline beyond a single product.
What is the main competitive advantage of Aurinia Pharmaceuticals?
Aurinia's primary competitive advantage is its approved product, LUPKYNIS, which addresses a serious autoimmune kidney condition with limited treatment options. The Otsuka partnership extends its commercial reach internationally without requiring full in-house infrastructure, providing leverage on its core asset.
What sector does AUPH belong to?
Aurinia Pharmaceuticals operates in the Healthcare sector, specifically within the specialty biopharmaceutical segment. It focuses on autoimmune and inflammatory diseases, with lupus nephritis as its primary commercial target. You can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score.
Unlock Full AUPH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access detailed financial metrics and trend data
- ✓Compare AUPH against sector peers side by side
- ✓Track Quality, Growth, Moat, Risk, and Valuation over time
- ✓Get the complete analyst-style view in one dashboard
Pro Analysis
AUPH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 70.0 | 93.1 | 41.0 | 71.0 | 90.6 | 72.1 | 0.0 |
| May 22, 2026 | 70.0 | 93.1 | 41.0 | 71.0 | 90.6 | 72.6 | -2.1 |
| May 21, 2026 | 72.1 | 93.1 | 41.0 | 71.0 | 90.6 | 72.1 | -0.1 |
| May 20, 2026 | 72.2 | 93.1 | 41.0 | 71.0 | 90.6 | 72.9 | +0.1 |
| May 19, 2026 | 72.1 | 93.1 | 41.0 | 71.0 | 90.6 | 71.6 | +2.1 |
| May 17, 2026 | 70.0 | 93.1 | 41.0 | 71.0 | 90.6 | 72.4 | 0.0 |
| May 16, 2026 | 70.0 | 93.1 | 41.0 | 71.0 | 90.6 | 72.6 | -2.2 |
| May 15, 2026 | 72.2 | 93.1 | 41.0 | 71.0 | 90.6 | 72.9 | 0.0 |
| May 14, 2026 | 72.2 | 93.1 | 41.0 | 71.0 | 90.6 | 72.4 | -0.5 |
| May 13, 2026 | 72.7 | 93.1 | 41.0 | 71.0 | 90.6 | 75.6 | -0.1 |
AUPH — Pillar Breakdown
Quality
— 93.1/100 (25%)Aurinia Pharmaceuticals Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 71.0/100 (20%)Aurinia Pharmaceuticals Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 90.6/100 (15%)Aurinia Pharmaceuticals Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 73.8/100 (15%)Aurinia Pharmaceuticals Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 41/100 (25%)Aurinia Pharmaceuticals Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AUPH.
Score Composition
Financial Data
More Stock Analysis
How is the AUPH UQS Score Calculated?
The UQS (Unified Quality Score) for Aurinia Pharmaceuticals Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Aurinia Pharmaceuticals Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Aurinia Pharmaceuticals Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.